The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during ...

Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline ...

US negotiates 71% cost reduction of Novo Nordisk’s obesity drugs for elderly Americans on government health insurance ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Novo Nordisk (NYSE: NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk announced new post hoc analysis data from the ESSENCE Phase 3 trial regarding the ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Shares of Novo Nordisk ($NVO), maker of the popular obesity drug Wegovy, rose over 2% early Tuesday on the weight loss ...

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

Keep an eye on Novo Nordisk: Trump struck a deal with drugmakers Eli Lilly and Novo Nordisk earlier this month for their ...

About the initiative: The initiative rejects the city’s current housing plan — which allows for more than 8,000 homes — and ...